Ixmyelocel-T

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dilated Cardiomyopathy

Conditions

Dilated Cardiomyopathy

Trial Timeline

Sep 1, 2008 → Sep 5, 2012

NCT ID

NCT00765518

About Ixmyelocel-T

Ixmyelocel-T is a phase 2 stage product being developed by Vericel for Dilated Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00765518. Target conditions include Dilated Cardiomyopathy.

What happened to similar drugs?

1 of 2 similar drugs in Dilated Cardiomyopathy were approved

Approved (1) Terminated (1) Active (0)

✅Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved

❌ARRY-371797 (PF-07265803)PfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01670981	Phase 2	Completed	Feb 20, 2013	Mar 7, 2018	Ischemic Dilated Cardiomyopathy (IDCM)
NCT01483898	Phase 3	Completed	Feb 1, 2012	Mar 25, 2014	Critical Limb Ischemia
NCT01020968	Phase 2	Completed	Dec 1, 2009	Dec 5, 2013	Dilated Cardiomyopathy
NCT00765518	Phase 2	Completed	Sep 1, 2008	Sep 5, 2012	Dilated Cardiomyopathy
NCT00505219	Phase 3	Completed	Sep 1, 2007	Dec 1, 2010	Osteonecrosis

Competing Products

10 competing products in Dilated Cardiomyopathy

See all competitors

Product	Company	Stage	Hype Score
Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin	AstraZeneca	Approved	43
AZD0233 + AZD0233 Placebo	AstraZeneca	Phase 1	21
AZD4063	AstraZeneca	Phase 1	36
ARRY-371797, p38 inhibitor, oral	Pfizer	Phase 2	35
ARRY-371797 (PF-07265803)	Pfizer	Phase 3	32
ARRY-371797, p38 inhibitor; oral	Pfizer	Phase 2	35
danicamtiv	Bristol Myers Squibb	Phase 2	27
Ixmyelocel-T	Vericel	Phase 2	29
ixmyelocel-T	Vericel	Phase 2	29
talfirastide	Constant Therapeutics	Phase 2	21